EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial

Koji Kato, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Yoshinobu Maeda, Kenichi Yoshimura, Ukihide Tateishi, Toshihiro Miyamoto, Yasufumi Matsuda, Jun Ishikawa, Shinya Rai, Tsutomu Takahashi und 5 weitere

International Journal of Hematology · 2024

DOI: 10.1007/s12185-024-03738-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Koji Kato und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582,…. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Bendamustine Hydrochloride, Rituximab, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Response determined by 18[F]-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)-CT after induction therapy can predict progression-free survival (PFS) in follicular lymphoma (FL). However, little prospective research has examined the significance of PET after second-line therapy. We conducted a prospective multicenter phase II trial (W-JHS NHL01) of bendamustine plus rituximab (BR) without rituximab maintenance for FL in first relapse. This study aimed to evaluate the usefulness of end-of-treatment (EOT)-PET for predicting PFS in FL patients in first relapse. EOT-PET examinations were performed between 6 and 8 weeks from the start of the last BR cycle. The primary endpoint was 1-year PFS. Key secondary endpoints were overall response rate (ORR), complete response rate (CRR), and 1-year overall survival (OS). Seventy-five patients were enrolled, and 8 were excluded from analysis. ORR was 86.6% and CRR was 59.7%. One-year PFS was 88.9% (95% confidence interval [CI] 80.7-94.3%) and 1-year OS in 75 patients was 97.3% (95% CI 89.6-99.3%). One-year PFS was significantly inferior in EOT-PET-positive patients (n = 9) compared with PET-negative patients (n = 58) (77.8% vs. 93.1%; p = 0.02). We confirmed that EOT-PET after second-line BR therapy could predict early progression in FL patients in first relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularBendamustine HydrochlorideRituximabFluorodeoxyglucose F18Antineoplastic Combined Chemotherapy ProtocolsDisease ProgressionPositron-Emission TomographyHumansMiddle AgedAgedMaleFemaleProspective StudiesAdultJapanRecurrenceAged, 80 and overRadiopharmaceuticals

Stichwörter der Autor:innen

BendamustineFDG–PETFollicular lymphomaPredictive factorRituximab

Substanzen

Bendamustine HydrochlorideRituximabFluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. kato.koji.429@m.kyushu-u.ac.jp.
  • Department of Hematology, Toranomon Hospital, Tokyo, Japan.
  • Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
  • Innovative Clinical Research Centre, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.

Zitieren

APA

Kato, K., Izutsu, K., Nishikori, M., Shibayama, H., Maeda, Y., Yoshimura, K., Tateishi, U., Miyamoto, T., Matsuda, Y., Ishikawa, J., Rai, S., Takahashi, T., Yamauchi, T., Matsumura, I., Akashi, K., Kanakura, Y., & Suzumiya, J. (2024). End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03738-8

Vancouver

Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, et al. End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03738-8

BibTeX
@article{Kato2024,
  author = {Kato, Koji and Izutsu, Koji and Nishikori, Momoko and Shibayama, Hirohiko and Maeda, Yoshinobu and Yoshimura, Kenichi and Tateishi, Ukihide and Miyamoto, Toshihiro and Matsuda, Yasufumi and Ishikawa, Jun and Rai, Shinya and Takahashi, Tsutomu and Yamauchi, Takahiro and Matsumura, Itaru and Akashi, Koichi and Kanakura, Yuzuru and Suzumiya, Junji},
  title = {End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial},
  journal = {International Journal of Hematology},
  year = {2024},
  doi = {10.1007/s12185-024-03738-8}
}
Kostenlos starten →